Pérez DI - Search Results

1

Increasing Brain Permeability of PHA-767491, a Cell Division Cycle 7 Kinase Inhibitor, with Biodegradable Polymeric Nanoparticles.

Rojas-Prats E, Tosat-Bitrián C, Martínez-González L, Nozal V, Pérez DI, Martínez A. Rojas-Prats E, et al. Among authors: perez di. Pharmaceutics. 2021 Jan 28;13(2):180. doi: 10.3390/pharmaceutics13020180. Pharmaceutics. 2021. PMID: 33525757 Free PMC article.

2

Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching.

Conde S, Pérez DI, Martínez A, Perez C, Moreno FJ. Conde S, et al. Among authors: perez di, perez c. J Med Chem. 2003 Oct 23;46(22):4631-3. doi: 10.1021/jm034108b. J Med Chem. 2003. PMID: 14561081

3

GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?

Martinez A, Perez DI. Martinez A, et al. Among authors: perez di. J Alzheimers Dis. 2008 Oct;15(2):181-91. doi: 10.3233/jad-2008-15204. J Alzheimers Dis. 2008. PMID: 18953107 Review.

4

Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools.

Perez DI, Conde S, Pérez C, Gil C, Simon D, Wandosell F, Moreno FJ, Gelpí JL, Luque FJ, Martínez A. Perez DI, et al. Among authors: perez c. Bioorg Med Chem. 2009 Oct 1;17(19):6914-25. doi: 10.1016/j.bmc.2009.08.042. Epub 2009 Aug 22. Bioorg Med Chem. 2009. PMID: 19747834

5

Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases.

Perez DI, Gil C, Martinez A. Perez DI, et al. Med Res Rev. 2011 Nov;31(6):924-54. doi: 10.1002/med.20207. Epub 2010 Jun 23. Med Res Rev. 2011. PMID: 20577972 Review.

6

Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds.

Perez DI, Palomo V, Pérez C, Gil C, Dans PD, Luque FJ, Conde S, Martínez A. Perez DI, et al. Among authors: perez c. J Med Chem. 2011 Jun 23;54(12):4042-56. doi: 10.1021/jm1016279. Epub 2011 May 17. J Med Chem. 2011. PMID: 21500862

7

The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy.

Palomo V, Perez DI, Gil C, Martinez A. Palomo V, et al. Among authors: perez di. Curr Med Chem. 2011;18(20):3028-34. doi: 10.2174/092986711796391697. Curr Med Chem. 2011. PMID: 21651477 Review.

8

Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment.

Martinez A, Gil C, Perez DI. Martinez A, et al. Among authors: perez di. Int J Alzheimers Dis. 2011;2011:280502. doi: 10.4061/2011/280502. Epub 2011 Jun 30. Int J Alzheimers Dis. 2011. PMID: 21760986 Free PMC article.

9

Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities.

Palomo V, Soteras I, Perez DI, Perez C, Gil C, Campillo NE, Martinez A. Palomo V, et al. Among authors: perez di, perez c. J Med Chem. 2011 Dec 22;54(24):8461-70. doi: 10.1021/jm200996g. Epub 2011 Nov 16. J Med Chem. 2011. PMID: 22050263

10

Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.

Redondo M, Zarruk JG, Ceballos P, Pérez DI, Pérez C, Perez-Castillo A, Moro MA, Brea J, Val C, Cadavid MI, Loza MI, Campillo NE, Martínez A, Gil C. Redondo M, et al. Among authors: perez castillo a, perez di, perez c. Eur J Med Chem. 2012 Jan;47(1):175-85. doi: 10.1016/j.ejmech.2011.10.040. Epub 2011 Nov 4. Eur J Med Chem. 2012. PMID: 22100138

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters